Virios Therapeutics Announces New Social Media Profiles
August 19 2021 - 7:05AM
Business Wire
Data from Ongoing Phase 2b Fibromyalgia
Trial Projected for Mid-2022
Virios Therapeutics, Inc. (Nasdaq: VIRI), a
clinical-stage biotechnology company focused on advancing novel
antiviral therapies to treat debilitating chronic diseases,
announced today the expansion of the company's social media
platforms as well as social media disclosure.
Virios has established a social presence on LinkedIn, Twitter
and Facebook, where current and potential investors and other
interested persons can connect with the company and receive future
updates. The Company plans to use the newly established social
media profiles in addition to the Company’s existing Investor
Relations website for the distribution of Company information.
Accordingly, investors should connect with Virios to monitor these
channels, along with following press releases, SEC filings and
public conference calls and webcasts. The links can be found below
to each of these platforms.
Content will include company news and updates as well as
educational, scientific-based posts regarding Herpes Simplex
Virus-1 ("HSV-1"), fibromyalgia, irritable bowel syndrome ("IBS"),
chronic fatigue syndrome ("CFS") and functional somatic syndrome,
all of which are characterized by a waxing and waning manifestation
of disease.
“With the recent news that all 41 sites involved in our ongoing
460 patient Phase 2b fibromyalgia ("FM") trial are now fully
activated and enrolling patients, now is the perfect time to expand
our digital presence through social media,” said Virios
Therapeutics CEO Greg Duncan.
Mr. Duncan continued, “The current trial builds on the
encouraging results from our previously completed 2a FM clinical
study that demonstrated our lead antiviral development candidate,
orally administered IMC-1, met its primary endpoint of pain
reduction and was statistically tolerated better than placebo. With
the new trial underway we are excited to share new results and
updates with investors and patients alike through these
platforms.”
Virios Therapeutics LinkedIn:
https://www.linkedin.com/company/ViriosBiotech/
Virios Therapeutics Twitter:
https://twitter.com/ViriosBiotech
Virios Therapeutics Facebook:
https://www.facebook.com/ViriosBiotech/
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage
biotechnology company focused on advancing novel antiviral
therapies to treat debilitating chronic diseases, such as
fibromyalgia (“FM”). Immune responses related to the activation of
tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been
postulated as a potential root cause triggering and/or sustaining
chronic illnesses such as FM, irritable syndrome (“IBS”), chronic
fatigue syndrome and other functional somatic syndromes, all of
which are characterized by waxing and waning symptoms with no
obvious etiology. Our lead development candidate (“IMC-1”) is a
novel, proprietary, fixed dose combination of famciclovir and
celecoxib designed to synergistically suppress HSV-1 replication,
with the end goal of reducing virally promoted disease
symptoms.
Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome
measures was previously demonstrated in a Phase 2a clinical trial.
These trial results are suggestive that IMC-1 may represent a new
and novel treatment for fibromyalgia. IMC-1 has been granted fast
track designation by the FDA and is currently being tested in a
multi-center, randomized, double-blind, placebo-controlled Phase 2b
trial (“FORTRESS”) designed to set the stage for registrational
studies. The company is led by an executive team highly experienced
in the successful development and commercialization of novel
therapies. For more information, please visit www.virios.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Virios Therapeutics’ current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict, including risks related to the
completion and timing of the Phase 2b trial. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2020 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Virios Therapeutics,
Inc. (VIRI) undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210819005057/en/
Dave Gentry 1-800-733-2447 +1-407-491-4498 dave@redchip.com or
ir@virios.com
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Apr 2023 to Apr 2024